Applied Therapeutics (NASDAQ:APLT) issued its earnings results on Monday. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.12), Bloomberg Earnings reports.
Shares of APLT opened at $9.36 on Wednesday. Applied Therapeutics has a 1-year low of $7.95 and a 1-year high of $11.20. The company’s 50-day moving average is $8.81.
In related news, major shareholder Real Estate Equitie Alexandria purchased 975,000 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was acquired at an average cost of $10.00 per share, for a total transaction of $9,750,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joel S. Marcus purchased 150,000 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were bought at an average price of $10.00 per share, with a total value of $1,500,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 1,250,000 shares of company stock valued at $12,500,000.
Applied Therapeutics Company Profile
Applied Therapeutics, Inc, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy.
Featured Story: How to Use the New Google Finance Tool
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.